Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma.

PURPOSE This study evaluated the role of anti-tumor immune response of curcumin on tongue squamous cell carcinama (TSCC). EXPERIMENTAL DESIGN Cell lines (Cal 27, FaDu) and animal model (4NQO mice model) were uesd in this study. The MTT assay was used to detecte cell proliferation. The Western blotting, immunohistochemistry and immunofluorescence were used to examine the protein expression. The flow cytometry was performed to determine the number of Treg and MDSC. RESULTS The expression of PD-L1 and p-STAT3Y705 were does-dependently inhibited in Fadu and Cal 27 cell line. The results of in vivo demonstrated that curcumin significantly attenuated tumor growth in 4NQO mice model. The expression of PD-L1 and p-STAT3Y705 were similarly decreased in vivo. Moreover, the anti-tumor immune response was remarkably improved after curcumin treatment through increasing CD8 positive T cells and decreasing Tregs and MDSCs. CONCLUSIONS Curcumin treatment resulted in inhibition of PD-L1 and p-STAT3Y705 expression both in vitro and in vivo. Moreover, the immunosuppressive tumor microenvironment was changed after curcumin treatment. These data suggested that curcumin could effectively promote anti-tumor immune response in TSCC.

[1]  Poul Erik Petersen,et al.  Oral Cancer Prevention and Control – the Approach of the World Health Organization , 2022 .

[2]  T. Rosol,et al.  Animal models of head and neck squamous cell carcinoma. , 2016, Veterinary journal.

[3]  R. Coletta,et al.  In vivo and in vitro effects of curcumin on head and neck carcinoma: a systematic review , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[4]  E. Mroz,et al.  Intra-tumor heterogeneity in head and neck cancer and its clinical implications , 2016, World journal of otorhinolaryngology - head and neck surgery.

[5]  B. Aggarwal,et al.  Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. , 2017, Clinical science.

[6]  N. Magné,et al.  Preclinical models in HNSCC: A comprehensive review. , 2017, Oral oncology.

[7]  Hong-gang Yu,et al.  CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells , 2016, Oncoimmunology.

[8]  Fazli Wahid,et al.  Curcumin in Cancer Chemoprevention: Molecular Targets, Pharmacokinetics, Bioavailability, and Clinical Trials , 2010, Archiv der Pharmazie.

[9]  G. Garlet,et al.  Relevance of CCL3/CCR5 axis in oral carcinogenesis , 2017, Oncotarget.

[10]  J. Weiss,et al.  Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/αCD40 Therapy , 2014, The Journal of Immunology.

[11]  S. Strome,et al.  The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. , 2014, Oral oncology.

[12]  Fu-Tsai Chung,et al.  Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer , 2009, Journal of Cancer Research and Clinical Oncology.

[13]  J. Califano,et al.  Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma , 2014, Clinical Cancer Research.

[14]  A. Kulkarni,et al.  STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC , 2017, Journal of dental research.

[15]  Miao-Fen Chen,et al.  Inflammation‐induced myeloid‐derived suppressor cells associated with squamous cell carcinoma of the head and neck , 2017, Head & neck.

[16]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[17]  Jianjiang Zhao,et al.  Increased frequency of CD4+ CD25+ FOXP3+ cells correlates with the progression of 4-nitroquinoline1-oxide-induced rat tongue carcinogenesis , 2013, Clinical Oral Investigations.

[18]  N. Kosaka,et al.  The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Y. Su,et al.  Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice. , 2012, Oral diseases.

[20]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[21]  G. Kristiansen,et al.  PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma , 2017, Oncotarget.

[22]  S. Agelaki,et al.  The promise of immunotherapy in head and neck squamous cell carcinoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Mohammad Reza Zamani,et al.  PD-1 and cancer: molecular mechanisms and polymorphisms , 2017, Immunogenetics.

[25]  Z. Qin,et al.  Transmembrane TNF-α Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2 , 2014, The Journal of Immunology.

[26]  M. Manjili,et al.  Role of Tregs in Cancer Dormancy or Recurrence , 2016, Immunological investigations.

[27]  K. Tanaka,et al.  Xeroderma pigmentosum group A gene action as a protection factor against 4-nitroquinoline 1-oxide-induced tongue carcinogenesis. , 2001, Carcinogenesis.

[28]  H. Harada,et al.  Clinical Course of Oral Squamous Cell Carcinoma in Patients on Immunosuppressant and Glucocorticoid Therapy. , 2017, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[29]  O. Stasikowska-Kanicka,et al.  Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma , 2017, Pathology & Oncology Research.

[30]  I. Durán,et al.  Biomarkers of response to PD-1/PD-L1 inhibition. , 2017, Critical reviews in oncology/hematology.

[31]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[32]  A. Chinnaiyan,et al.  Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression , 2018, The Journal of clinical investigation.